FMDV VACCINE: Biosafe coronavirus vector-based vaccine for prevention of foot-and-mouth disease

• Research unit: EU RFP
• Project number: 02.0093

Key words (English)

Life Sciences; Medicine; Health; Safety; Scientific Research; Social Aspects

Alternative project number (English)

EU project number: QLK-CT-2002-00825

Research programs (English)

EU-programme: 5. Frame Research Programme - 1.1.2 Control of infectious diseases

Short description (English)

See abstract

Further information (English)

Full name of research-institution/enterprise:
Bundesamt für Veterinärwesen BVET
Institut für Viruskrankheiten u. Immunprophylaxe IVI
Sektion Immunologie

Abstract (English)

A previously developed biosafe transmissible gastroenteritis virus (TGEV) -based vector will be engineered to amplify foot-and-mouth disease capsid proteins, to serve as a marked vaccine against FMD. In addition to the biosafety features of the TGEV-based vector, constructions will include exclusively FMDV protease JC andP1-2A (to produce virus-like particles in situa and or a fragment of 3D so that no FMDV can be produced. The TGEV chosen replicates in the enteric and respiratory tracts which are very adequate replication in the enteric and respiratory Antigen expression, immune responses, protection against challenge with virulent FMDV, and possible virus transmission after challenge will be examined using wine, one of the major animal hosts for FMDV. Constructs expressing 20 amino acid sequences of the major antigenic site of FMDV-O and FMDV-C will also be tested in an attempt to broader the immune response.

References in databases (English)

Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. [phone]
Swiss Project-Number: 02.0093